- Home
- FLC vs SAVA Comparison
FLC vs SAVA Comparison
Compare FLC & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | SAVA |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 156.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FLC | SAVA |
|---|---|---|
| Price | $17.41 | $2.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 37.8K | ★ 977.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.62 | $1.15 |
| 52 Week High | $15.45 | $4.98 |
Technical Indicators
Market Signals| Indicator | FLC | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 39.81 |
| Support Level | $17.39 | $1.96 |
| Resistance Level | $17.60 | $2.16 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 59.30 | 25.25 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.